辉瑞三季净赚49亿美元,100亿收购Metsera布局减重市场

ITBEAR科技资讯
Nov 12

近期,国内创新药市场因BD交易(生物医药授权交易)的频繁发生而迎来新一轮行情。这一现象背后,折射出跨国药企(MNC)在补充研发管线、应对市场竞争压力时的迫切需求。相较于国内创新药企业的活跃表现,多家全球头部药企的市场表现却陷入低迷,引发行业对未来竞争格局的深度关注。强生、辉瑞、诺和诺德等国际药企巨头近期股价持续承压。以诺和诺德为例,这家因减肥药司美格鲁肽(Wegovy)而声名鹊起的丹麦药企,过去...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10